We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience
News

GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience

GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience
News

GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compendia Bioscience has announced that it has signed a two-year licensing agreement with GlaxoSmithKline for Oncomine Enterprise Edition, a value-added product extension Compendia’s flagship product, Oncomine.

Oncomine Enterprise Edition builds upon the features of Oncomine Professional and Concepts editions by integrating the ability to securely view proprietary gene expression data in comparison with existing public data already available in Oncomine.

Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number profiles collected and curated from the literature and other public sources. These data are coupled with analysis functions and a web application for data mining and visualization.

Oncomine Concepts Map, licensed to commercial users as part of the Oncomine Enterprise Edition, uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways.

“We are pleased to welcome GlaxoSmithKline to our growing list of major pharmaceutical and biotech customers,” said John Freshley, Chief Business Officer of Compendia Bioscience. “GSK has long been a leader in the field of cancer genomics and we look forward to working closely with them to advance their oncology discovery and development efforts.”

Advertisement